Document is current

Article History

Received: 7 August 2025

Accepted: 15 September 2025

First Online: 1 October 2025

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all participants enrolled in the study.

: Consent to publish has been received from all participants.

: Hartmut Goldschmidt declares the following:Grants and/or provision of Investigational Medicinal Product: Amgen, Array Biopharma/Pfizer, BMS/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi.Research Support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis.Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Janssen, Sanofi, Honoraria / Nebentätigkeiten: Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer.Support for attending meetings and/or travel: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer.Elias K. Mai reports the following:Consulting or advisory role: Bristol Myers Squibb/Celgene, GlaxoS- mithKline, Janssen-Cilag, Sanofi Aventis, Stemline, Takeda.Honoraria: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen- Cilag, Sanofi Aventis, Stemline, Takeda.Research funding: Sanofi Aventis.Travel accommodations and expenses: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi Aventis, Stemline, Takeda.All other authors declare no conflicts of interest.